In conclusion, we define PRKD3 to be a key regulator of CLU in promoting TNBC tumor growth, and provide new promising targeted therapies against CLU pathway via targeting CLU and PRKD3 as well as serum sCLU as a blood‐based biomarker for efficient management of TNBC (Figure 8G). The gene discussed is PRKD3; the disease is neoplasm.